Galafold (migalastat) is an oral medication that must be taken precisely as prescribed by a doctor experienced in the diagnosis and treatment of Fabry disease.

• Formulation: Galafold is available as a 123 mg capsule.
• Administration Method: The capsule should be swallowed whole with water. Do not cut, crush, chew, or open the capsule.
• Dosage Schedule: The recommended dose is one capsule (123 mg) orally once every other day. It is crucial to take it at the same time of day to maintain consistent levels in your body.
• Do NOT take on consecutive days. Galafold is specifically dosed every other day.
• On an Empty Stomach: Galafold must be taken on an empty stomach. This means you should not consume any food for at least 2 hours before and 2 hours after taking the capsule. You can consume clear liquids (like plain water, flavored water, or fruit juices without pulp, and caffeine-free carbonated beverages) during this 4-hour fasting period.
• Missed Dose:
  • If you miss a dose, take the missed dose only if it is within 12 hours of the time it should have been taken.
  • If more than 12 hours have passed, do not take the missed dose. Instead, skip it and resume taking Galafold at the next planned dosing day and time, following your regular every-other-day schedule. Do not take two doses at one time.
• Storage: Store Galafold capsules at room temperature, away from moisture and heat. Keep unused capsules in their original blister pack.

Consistent adherence to the dosing schedule and fasting instructions is vital for Galafold’s effectiveness.

Fabry disease occurs due to a faulty GLA gene, which leads to a deficiency or malfunction of the alpha-galactosidase A (alpha-Gal A) enzyme. This enzyme normally breaks down a fatty substance called globotriaosylceramide (GL-3). When alpha-Gal A is deficient or dysfunctional, GL-3 builds up in various cells and organs, causing the symptoms of Fabry disease.

Galafold (migalastat) is a pharmacological chaperone. Here’s how it works:

• Binding and Stabilization: Migalastat selectively and reversibly binds to certain unstable, misfolded forms of the alpha-Gal A enzyme.
• Proper Trafficking: By binding, Galafold helps stabilize these misfolded enzymes, allowing them to fold correctly and be transported effectively from the endoplasmic reticulum (where they are made) to the lysosomes (where they are supposed to function). Normally, misfolded enzymes are recognized as faulty and broken down before they reach the lysosomes.
• Enzyme Activity Restoration: Once inside the lysosome, where the environment (lower pH and high concentration of GL-3) is different, Galafold dissociates from the alpha-Gal A enzyme. This releases the now properly folded and functional enzyme, allowing it to perform its role of breaking down accumulated GL-3 and related fatty substances.
• Reduction of Substrate: By restoring the activity of the enzyme, Galafold helps reduce the buildup of GL-3 in the body’s cells and tissues.

This targeted approach helps the body use its own existing, albeit misfolded, enzyme more efficiently.

Like all medications, Galafold (migalastat) can cause side effects, although not everyone experiences them. Most common side effects are generally mild.

Common side effects (occurring in 10% or more of patients) may include:

• Headache
• Nasopharyngitis (common cold symptoms like stuffy nose, sneezing, sore throat)
• Urinary tract infection (UTI)
• Nausea
• Pyrexia (fever)

Less common (1% to less than 10%) side effects can include:

• Abdominal pain
• Back pain
• Cough
• Diarrhea
• Epistaxis (nosebleed)
• Dizziness
• Fatigue
• Vomiting
• Arthralgia (joint pain)
• Peripheral edema (swelling of hands/feet)

Serious, but rare, side effects that require immediate medical attention:

• Allergic reactions: Signs of an allergic reaction include hives, difficulty breathing, swelling of your face, lips, tongue, or throat. Seek emergency medical help immediately if these occur.
• Pain or burning when you urinate (which could be a sign of a serious UTI).

It’s important to report any new, unusual, or severe symptoms to your doctor or healthcare provider.

Galafold is a specialized medication for a serious genetic disorder, and its use comes with important warnings and precautions:

• Amenable GLA Variant Required: Galafold is only effective for patients with specific “amenable” mutations in the GLA gene. Patients must undergo genetic testing to confirm they have such a variant before starting treatment. Not all Fabry patients are candidates for Galafold.
• Renal Impairment: Galafold is primarily eliminated by the kidneys. While it has not been studied in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease (ESRD) requiring dialysis, its use is not recommended in these patient populations. Your doctor will assess your kidney function before and during treatment.
• Allergic Reactions: Hypersensitivity reactions, including angioedema (swelling beneath the skin), have been reported. If signs of an allergic reaction occur, discontinue Galafold and seek immediate medical attention.
• Pregnancy and Lactation:
  • Pregnancy: There is insufficient clinical data on Galafold use in pregnant women to determine a drug-associated risk for major birth defects or miscarriage. Use in pregnancy only if the potential benefit outweighs the potential risk to the fetus. A pregnancy registry is available to monitor outcomes.
  • Lactation: It is unknown if Galafold is present in human milk. Given that many drugs are excreted in human milk, and the potential for adverse effects on breastfed infants, the decision to breastfeed during treatment should consider the mother’s clinical need for Galafold and any potential risks to the infant.
• Pediatric Use: Galafold is approved for adolescents aged 12 years and older. Its safety and effectiveness have not been established in pediatric patients younger than 12 years.
• Fertility: In animal studies, Galafold caused transient and reversible infertility in male rats at exposures equivalent to the human recommended dose. The effects on human fertility have not been studied.
• Monitoring: Patients on Galafold should be monitored regularly by a doctor experienced in Fabry disease. This may include monitoring clinical symptoms, biochemical markers (like GL-3 levels), and organ function (kidney, heart).

Galafold (migalastat) has a relatively low potential for drug-drug interactions through common metabolic pathways. This is because it is primarily eliminated unchanged by the kidneys and does not significantly inhibit or induce major cytochrome P450 (CYP450) liver enzymes or transporter proteins.

However, there is one important interaction to be aware of:

• Caffeine: Co-administration of Galafold with caffeine can decrease the absorption (AUC and Cmax) of migalastat, potentially reducing its effectiveness. Therefore, it is advised to avoid consuming caffeine for at least 2 hours before and 2 hours after taking Galafold. This means a minimum 4-hour fasting period from caffeine around the dosing time.

Always inform your doctor, pharmacist, and healthcare team about all medications you are currently taking, including:

• Prescription drugs
• Over-the-counter medications
• Vitamins
• Herbal supplements

While direct interactions are generally minimal, your healthcare provider needs a complete picture of your health to ensure the safe and effective use of Galafold, especially considering the rarity of Fabry disease and its potential impact on multiple organ systems.

The dosage of Galafold (migalastat) is fixed for eligible patients and follows a specific every-other-day schedule.

• Recommended Dose: 123 mg (one capsule) taken orally.
• Frequency: Once every other day. It is crucial to adhere strictly to this every-other-day schedule and not take it on consecutive days.
• Timing: Take the capsule at the same time of day to maintain consistency.
• Fasting Requirements: Must be taken on an empty stomach.
  • No food for at least 2 hours before the dose.
  • No food for at least 2 hours after the dose.
  • This creates a minimum 4-hour fasting period around the dosing time.
  • Clear liquids (water, pulp-free juice, caffeine-free carbonated beverages) are allowed during the fasting period.
• Missed Dose Protocol:
  • If you miss a dose, take it only if it is within 12 hours of your regular dosing time.
  • If more than 12 hours have passed, skip the missed dose and resume your next scheduled dose on the subsequent “every other day” at your usual time. Do not take a double dose.
• Patient Amenability: Dosage is only applicable to patients confirmed to have an amenable GLA gene variant based on in vitro assay data.

Strict adherence to these guidelines is vital for the optimal effectiveness of Galafold.

Galafold (migalastat) is a prescription-only medication (POM). It is never available over-the-counter in Pakistan or any other regulated healthcare system globally. Its stringent prescription requirements are due to several critical factors:

• Targeted and Complex Indication: Galafold treats a rare, complex genetic disorder (Fabry disease) and is only effective for specific genetic mutations. This requires precise diagnosis and genetic testing.
• Specialist Oversight: Treatment must be initiated and supervised by a doctor who is highly experienced in the diagnosis and treatment of Fabry disease.
• Specific Patient Selection: Only patients with confirmed Fabry disease and an “amenable” GLA gene variant (determined by specialized genetic testing) are eligible for this therapy.
• Monitoring Requirements: Patients require ongoing monitoring for disease progression, response to treatment, and potential side effects, often involving specialized assessments.
• High Cost and Orphan Drug Status: As an orphan drug for a rare disease, its cost is typically high, and its distribution is carefully managed by pharmaceutical companies and healthcare systems.

Therefore, a licensed medical doctor, typically a specialist in rare genetic disorders, a nephrologist, a neurologist, or a cardiologist experienced in Fabry disease, must prescribe Galafold.

What is Galafold used for? Treatment of Fabry disease in adults with amenable GLA gene variants

2. What is the active ingredient? Migalastat hydrochloride

3. What drug class does it belong to? Miscellaneous metabolic agents (pharmacological chaperone)

4. Is Galafold a controlled substance? No

5. Is Galafold available in generic form? No

6. How is Galafold administered? Orally, as capsules

7. What strengths are available? 123 mg capsules

8. What is the usual adult dosage? 123 mg orally every other day

9. Can it be used in children? Not approved for pediatric patients

10. What are common side effects? Headache, nausea, urinary tract infection, abdominal pain

11. Can it cause serious reactions? Yes—hypersensitivity reactions, worsening of Fabry symptoms if variant is not amenable

12. Is Galafold safe during pregnancy? Limited data; use only if benefits outweigh risks

13. Is a prescription required? Yes

14. Is Galafold available in Pakistan? Not widely; may be accessed via international specialty import

15. How should it be stored? At 20–25°C; protect from moisture and light

16. What precautions should be taken during use? Confirm amenable GLA variant before prescribing; monitor Fabry symptoms

17. What are contraindications? Hypersensitivity to migalastat; non‑amenable GLA variants

18. What monitoring is needed during use? Kidney function, cardiac status, Fabry symptom progression

19. Can Galafold be combined with enzyme replacement therapy (ERT)? No—should not be used concurrently with ERT

20. What are similar drugs? Enzyme replacement therapies for Fabry disease: Fabrazyme (agalsidase beta), Replagal (agalsidase alfa)